CBR1 and hepatocellular carcinoma: The study of Huang et al. demonstrated EGCG overcame the chemotherapy resistance of hepatoma cells to daunorubicin and reduce the cardiotoxicity of daunorubicin through directly targeting carbonyl reductase 1 (CBR1) to inhibit the conversion of daunorubicin to daunorubicinol (Huang et al., 2010).